West Pharmaceutical Services has attracted a notable analyst upgrade this week. The signals are pointing in the same direction.
Morgan Stanley upgraded WST to Overweight on September 22, raising its price target to $400 from $365. Analyst Kallum Titchmarsh's move marks a meaningful shift — the firm had held an Equal-Weight stance since at least July, when it last raised the target to $365.
The upgrade puts Morgan Stanley in line with an increasingly bullish analyst pack. UBS raised its target to $415 on September 9. Citigroup lifted to $412 in August. Evercore ISI stands at $425. The consensus mean target is now $407.56, implying roughly 9% upside from Wednesday's close of $373.60.
The buy consensus rating is backed by four Outperform ratings and one Hold. No analysts currently rate the stock a Sell.
The borrow market is telling a similar story. Cost to borrow has dropped 51% in one week — from around 0.37% to just 0.18% as of September 24. That is the lowest level in the 30-day history shown, and down 59% over the month.
Availability stands at 4,232% — far above the 52-week minimum of 1,626%. There are roughly 59.5 million shares available to borrow against just 2.3 million shares short. Bears are not pressing the position. Short interest sits at 3.3% of free float, a modest level that has barely budged over the past month.
Next earnings are scheduled for October 29. The most recent print, on July 23, saw the stock fall 8.4% on the day and another 5.3% over the following week. That creates a known near-term volatility point.
The put/call ratio currently sits at 0.84 — slightly above the 20-day mean of 0.79 but well within normal range (z-score: 0.52). Options markets are not flashing unusual hedging activity.
See the live data behind this article on ORTEX.
Open WST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
